Related references
Note: Only part of the references are listed.Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Identifying newly approved medications in Medicare claims data: a case study using tocilizumab
Jeffrey R. Curtis et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2013)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis
Juan Gomez-Reino
RHEUMATOLOGY (2012)
Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey
Daniel H. Solomon et al.
ARTHRITIS CARE & RESEARCH (2012)
Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans
Gabriela Schmajuk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort
Jie Zhang et al.
ARTHRITIS CARE & RESEARCH (2011)
Validation of rheumatoid arthritis diagnoses in health care utilization data
Seo Young Kim et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Medicare Reimbursement and the Use of Biologic Agents: Incentives, Access, the Public Good, and Optimal Care
Michael M. Ward
ARTHRITIS CARE & RESEARCH (2010)
Biologic drugs for rheumatoid arthritis in the medicare program
Allan J. Wailoo et al.
ARTHRITIS AND RHEUMATISM (2008)
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal
Gabriela Schmajuk et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Y-F Chen et al.
HEALTH TECHNOLOGY ASSESSMENT (2006)
Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians' prescribing behavior
EM DeWitt et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions
AH Anis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2005)
Gaps in care for rheumatoid arthritis: A population study
D Lacaille et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
JM Bathon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
